Richard Afriyie Osei

Richard Afriyie Osei

Auto-generated profile, based on publicly available information

Richard Afriyie Osei

Department of Nanoscience, University of North Carolina at Greensboro, Greensboro, NC, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2026
Verified
Journal Article
Open access
PDF file
RORichard Afriyie Osei
Richard Afriyie Osei
OOOlaitan Ebenezer Oluwadare
Olaitan Ebenezer Oluwadare
OAOlatunde Simeon Awolola
Olatunde Simeon Awolola
The integration of patient-derived cancer organoids with artificial intelligence (AI) offers a potential approach for developing more individualised models of tumour behaviour and therapeutic response. Conventional precision oncology relies heavily on static molecular measurements, which may not fully capture intratumoural heterogeneity, treatment-induced adaptation, therapeutic resistance, or tumour evolution. Cancer organoids provide a functional experimental representation of patient-derived tumour biology, while AI enables the analysis and integration of complex molecular, phenotypic, imaging, and clinical data. Together, these technologies could provide a foundation for patient-specific computational models capable of predicting treatment response and adapting as new biological and clinical information becomes available. This critical review examines the biological fidelity of cancer organoids, the application of AI to organoid phenotyping and drug-response prediction, and the potential integration of these systems within a cancer digital-twin framework. Particular attention is given to intratumoural heterogeneity, clonal selection, culture-induced changes, incomplete representation of the tumour microenvironment, multimodal data integration, longitudinal updating, uncertainty quantification, and clinical validation. We argue that combining organoids with AI does not, by itself, constitute a digital twin. A clinically credible cancer organoid digital twin requires patient specificity, biological fidelity, multimodal integration, longitudinal updating, predictive capability, uncertainty awareness, and clinical actionability. The field therefore remains at an emerging translational stage. Future progress will depend on standardised organoid workflows, larger longitudinal datasets, improved modelling of the tumour microenvironment, hybrid mechanistic–AI approaches, and prospective multicentre validation. If these challenges are addressed, cancer organoid digital twins could shift precision oncology from static tumour characterisation towards dynamic prediction of treatment response, resistance, and tumour evolution.

6 October 2026 in Oncology, Nuclear Medicine and Transplantology
Verified
Journal Article
Open access
PDF file
RORichard Afriyie Osei
Richard Afriyie Osei
DTDanmegoro Suleman Taiye
Danmegoro Suleman Taiye
GNGodwin Kenechukwu Nwajiugo
Godwin Kenechukwu Nwajiugo
OOOluwabukunmi Oluwaniran
Oluwabukunmi Oluwaniran
IMIsmaila Muhammed
Ismaila Muhammed
Cancer behaves as a dynamic evolutionary system, whereas conventional tissue biopsy and imaging provide incomplete temporal information about how a tumour is changing. This review critically examines whether longitudinal liquid-biopsy measurement, combined with artificial intelligence (AI), can move oncology from tumour monitoring toward genuine prediction of cancer evolution and treatment resistance. We synthesise mechanistic, clinical, and computational evidence on circulating tumour DNA, circulating tumour cells, extracellular vesicles, and multimodal liquid-biopsy platforms, together with AI approaches applied to longitudinal cancer data, drawing on landmark and recent studies across colorectal, lung, breast, and ovarian cancer. Current evidence distinguishes three increasingly demanding tasks: early detection, longitudinal monitoring, and genuine forecasting. Longitudinal circulating tumour DNA analysis can detect molecular progression and emerging resistance mutations months before radiographic progression, and machine-learning models can stratify survival using serial biomarker metrics; however, most published "AI prediction" studies demonstrate earlier detection or prognostic association rather than prospectively validated forecasting of a future, patient-specific event. Biological variability in tumour shedding, analytical noise, small and irregularly sampled longitudinal datasets, overfitting, data leakage, weak external validation, and limited interpretability constrain the transition from detection to actionable prediction. AI-enabled liquid biopsy has genuine potential to forecast tumour trajectories, but current evidence is considerably stronger for molecular monitoring and early detection than for prospectively validated, clinically actionable prediction. Realising this potential will require standardised assays, prospective longitudinal cohorts with predefined prediction horizons, rigorous external and temporal validation, calibrated and interpretable models, and interventional trials linking predictions to treatment decisions before AI-enabled liquid biopsy can be considered ready to guide clinical care.

10 December 2025 in Oncology, Nuclear Medicine and Transplantology
Verified
Journal Article
Closed access
OOOluchi Okechukwu
Oluchi Okechukwu
CGChidinma Gab-Obinna
Chidinma Gab-Obinna
AOAdepeju Kafayat Olowookere
Adepeju Kafayat Olowookere
CJChristopher Bijabdo Jato
Christopher Bijabdo Jato
RORichard Afriyie Osei
Richard Afriyie Osei
LALawrence John Ajutor
Lawrence John Ajutor
Pathogen-reduction technologies (PRTs) methods for platelet and plasma are increasingly being relied on to inactivate a broad spectrum of pathogens to ensure safety in transfusion. However, there is continuing debate about the impact of such technology on clinical effectiveness, bleeding outcomes, and transfusion-related adverse events. Objective: This systematic review evaluated the clinical effectiveness and safety of PRT-treated platelets and plasma using studies published between 2015 and 2025. Methods: Following PRISMA 2020 guidelines, major databases including PubMed, Scopus, Embase, Web of Science, and Google Scholar were searched for studies published between 2015 and 2025. Eligible studies included human studies, platelet and/or plasma products that have been treated with specific PRT technology. A total of 1256 records were identified. Findings were synthesized narratively and presented descriptively. Results: Fifteen qualifying studies utilizing pathogen-reduced platelets and plasma from various areas were included. In randomized trials, platelets treated with PRT consistently exhibited decreased CCI at both 1 hour and 24 hours compared to conventional platelets, with certain studies indicating greater platelet use. Even though the platelet increments were lower, most trials did not report any significant rise in WHO grade ≥2 clinical bleeding, and the hemostatic efficacy was still satisfactory. Safety outcomes were relatively good: datasets showed that transfusion-reaction rates were low (<1%) and major adverse events were not so common. PRT systems showed strong pathogen-inactivation abilities, including the ability to effectively inactivate clinically important viruses such as hepatitis viruses, dengue, and Japanese encephalitis virus. Different technologies had different results, and UVC-based systems sometimes showed smaller increases after transfusions. Conclusion: Platelets and plasma treated with PRT are still clinically useful and very safe. They also greatly lower the risk of infections that can be spread by transfusions. Even though there are fewer laboratory increments and more platelet use, these changes don't seem to affect clinical hemostasis. Strengthening implementation methods, inventory planning, and hemovigilance systems alongside continuing evaluation of performance will enable safer transfusion procedures and safeguard vulnerable patient groups globally.